A
Anja Feldmann
Researcher at Max Planck Society
Publications - 368
Citations - 18932
Anja Feldmann is an academic researcher from Max Planck Society. The author has contributed to research in topics: The Internet & Antigen. The author has an hindex of 67, co-authored 340 publications receiving 17422 citations. Previous affiliations of Anja Feldmann include Saarland University & AT&T.
Papers
More filters
Proceedings ArticleDOI
Competitive analysis for service migration in VNets
Marcin Bienkowski,Anja Feldmann,Dan Jurca,Wolfang Kellerer,Gregor Schaffrath,Stefan Schmid,Joerg Widmer +6 more
TL;DR: An optimal offline algorithm based on dynamic programming techniques to find the best migration paths for a given request sequence, and a O(¼ log n)-competitive migration strategy MIG where ¼ is the ratio between maximal and minimal link capacity in the substrate network for a simplified model are presented.
Journal ArticleDOI
Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy.
Claudia Arndt,Frederick Fasslrinner,Liliana R. Loureiro,Stefanie Koristka,Stefanie Koristka,Anja Feldmann,Anja Feldmann,Michael Bachmann +7 more
TL;DR: An overview on the different adaptor CAR platforms available is provided, the possibilities and challenges of adaptorCAR therapy are discussed, and the first clinical experiences are summarized.
Proceedings ArticleDOI
A Multi-perspective Analysis of Carrier-Grade NAT Deployment
Philipp M. Richter,Florian Wohlfart,Narseo Vallina-Rodriguez,Mark Allman,Randy Bush,Anja Feldmann,Christian Kreibich,Nicholas Weaver,Vern Paxson +8 more
TL;DR: In this paper, the authors present a broad and systematic study of the deployment and behavior of CGN middleboxes and develop a methodology to detect the existence of hosts behind CGNs by extracting non-routable IP addresses from peer lists.
Journal ArticleDOI
Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells.
Liliana R. Loureiro,Liliana R. Loureiro,Liliana R. Loureiro,Anja Feldmann,Ralf Bergmann,Stefanie Koristka,Nicole Berndt,Nicole Berndt,Claudia Arndt,Jens Pietzsch,Jens Pietzsch,Carlos Novo,Paula A. Videira,Michael Bachmann +13 more
TL;DR: The previously described universal modular antibody-based platform technology named UniCAR may be used, and both activity and potential adverse effects of UniCAR T cells may be tunable by dosing TM infusions, to overcome limitations of the current CAR technology.
Journal ArticleDOI
Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells
Slava Stamova,Marc Cartellieri,Anja Feldmann,Claudia C. Bippes,Holger Bartsch,Rebekka Wehner,Marc Schmitz,M von Bonin,Martin Bornhäuser,G. Ehninger,Ernst Peter Rieber,Michael Bachmann +11 more
TL;DR: Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells is reported.